Trial Outcomes & Findings for p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246 (NCT NCT02098343)

NCT ID: NCT02098343

Last Updated: 2025-03-17

Results Overview

DLT: Hematological and non-hematological toxicities according to grade/days stated in the protocol.

• Recruitment status: COMPLETED
• Study phase: PHASE1/PHASE2
• Target enrollment: 247 participants
• Primary outcome timeframe: Until the end of the first treatment cycle, i.e., Day 28
• Results posted on: 2025-03-17

Participant Flow

Participant milestones

Measure	Phase Ib. APR-246 (35mg/kg) + Carboplatin/PLD. Dose escalation of APR-246. APR-246: Intravenous infusion. Carboplatin and Pegylated Liposomal Doxorubicin Hydrochloride (PLD): Intravenous infusion.	Phase Ib. APR-246 (50mg/kg) + Carboplatin/PLD. Dose escalation of APR-246. APR-246: Intravenous infusion. Carboplatin and Pegylated Liposomal Doxorubicin Hydrochloride (PLD): Intravenous infusion.	Phase Ib. APR-246 (67.5mg/kg) + Carboplatin/PLD. Dose escalation of APR-246. APR-246: Intravenous infusion. Carboplatin and Pegylated Liposomal Doxorubicin Hydrochloride (PLD): Intravenous infusion.	Phase II: Arm A. APR-246 + Carboplatin/PLD. Experimental APR-246: Intravenous infusion. Carboplatin and Pegylated Liposomal Doxorubicin Hydrochloride (PLD): Intravenous infusion.	Phase II: Arm B. Carboplatin/PLD. Active Comparator Carboplatin and Pegylated Liposomal Doxorubicin Hydrochloride (PLD): Intravenous infusion.
Overall Study STARTED	9	6	21	105	106
Overall Study COMPLETED	9	6	20	105	106
Overall Study NOT COMPLETED	0	0	1	0	0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

36 patients were enrolled in the Phase Ib study. One patient from the 67.5 mg/kg dose cohort was withdrawn from the study prior to initiating APR-246 treatment due to Investigator's decision.

Baseline characteristics by cohort

Measure	Phase Ib. APR-246 (35mg/kg) + Carboplatin/PLD. n=9 Participants Dose escalation of APR-246. APR-246: Intravenous infusion. Carboplatin and Pegylated Liposomal Doxorubicin Hydrochloride (PLD): Intravenous infusion.	Phase Ib. APR-246 (50mg/kg) + Carboplatin/PLD. n=6 Participants Dose escalation of APR-246. APR-246: Intravenous infusion. Carboplatin and Pegylated Liposomal Doxorubicin Hydrochloride (PLD): Intravenous infusion.	Phase Ib. APR-246 (67.5mg/kg) + Carboplatin/PLD. n=20 Participants Dose escalation of APR-246. APR-246: Intravenous infusion. Carboplatin and Pegylated Liposomal Doxorubicin Hydrochloride (PLD): Intravenous infusion.	Phase II: Arm A. APR-246 + Carboplatin/PLD. n=105 Participants Experimental APR-246: Intravenous infusion. Carboplatin and Pegylated Liposomal Doxorubicin Hydrochloride (PLD): Intravenous infusion.	Phase II: Arm B. Carboplatin/PLD. n=106 Participants Active Comparator Carboplatin and Pegylated Liposomal Doxorubicin Hydrochloride (PLD): Intravenous infusion.	Total n=246 Participants Total of all reporting groups
Age, Categorical <=18 years	0 Participants n=5 Participants • 36 patients were enrolled in the Phase Ib study. One patient from the 67.5 mg/kg dose cohort was withdrawn from the study prior to initiating APR-246 treatment due to Investigator's decision.	0 Participants n=7 Participants • 36 patients were enrolled in the Phase Ib study. One patient from the 67.5 mg/kg dose cohort was withdrawn from the study prior to initiating APR-246 treatment due to Investigator's decision.	0 Participants n=5 Participants • 36 patients were enrolled in the Phase Ib study. One patient from the 67.5 mg/kg dose cohort was withdrawn from the study prior to initiating APR-246 treatment due to Investigator's decision.	0 Participants n=4 Participants • 36 patients were enrolled in the Phase Ib study. One patient from the 67.5 mg/kg dose cohort was withdrawn from the study prior to initiating APR-246 treatment due to Investigator's decision.	0 Participants n=21 Participants • 36 patients were enrolled in the Phase Ib study. One patient from the 67.5 mg/kg dose cohort was withdrawn from the study prior to initiating APR-246 treatment due to Investigator's decision.	0 Participants n=8 Participants • 36 patients were enrolled in the Phase Ib study. One patient from the 67.5 mg/kg dose cohort was withdrawn from the study prior to initiating APR-246 treatment due to Investigator's decision.
Age, Categorical Between 18 and 65 years	5 Participants n=5 Participants • 36 patients were enrolled in the Phase Ib study. One patient from the 67.5 mg/kg dose cohort was withdrawn from the study prior to initiating APR-246 treatment due to Investigator's decision.	4 Participants n=7 Participants • 36 patients were enrolled in the Phase Ib study. One patient from the 67.5 mg/kg dose cohort was withdrawn from the study prior to initiating APR-246 treatment due to Investigator's decision.	10 Participants n=5 Participants • 36 patients were enrolled in the Phase Ib study. One patient from the 67.5 mg/kg dose cohort was withdrawn from the study prior to initiating APR-246 treatment due to Investigator's decision.	69 Participants n=4 Participants • 36 patients were enrolled in the Phase Ib study. One patient from the 67.5 mg/kg dose cohort was withdrawn from the study prior to initiating APR-246 treatment due to Investigator's decision.	57 Participants n=21 Participants • 36 patients were enrolled in the Phase Ib study. One patient from the 67.5 mg/kg dose cohort was withdrawn from the study prior to initiating APR-246 treatment due to Investigator's decision.	145 Participants n=8 Participants • 36 patients were enrolled in the Phase Ib study. One patient from the 67.5 mg/kg dose cohort was withdrawn from the study prior to initiating APR-246 treatment due to Investigator's decision.
Age, Categorical >=65 years	4 Participants n=5 Participants • 36 patients were enrolled in the Phase Ib study. One patient from the 67.5 mg/kg dose cohort was withdrawn from the study prior to initiating APR-246 treatment due to Investigator's decision.	2 Participants n=7 Participants • 36 patients were enrolled in the Phase Ib study. One patient from the 67.5 mg/kg dose cohort was withdrawn from the study prior to initiating APR-246 treatment due to Investigator's decision.	10 Participants n=5 Participants • 36 patients were enrolled in the Phase Ib study. One patient from the 67.5 mg/kg dose cohort was withdrawn from the study prior to initiating APR-246 treatment due to Investigator's decision.	36 Participants n=4 Participants • 36 patients were enrolled in the Phase Ib study. One patient from the 67.5 mg/kg dose cohort was withdrawn from the study prior to initiating APR-246 treatment due to Investigator's decision.	49 Participants n=21 Participants • 36 patients were enrolled in the Phase Ib study. One patient from the 67.5 mg/kg dose cohort was withdrawn from the study prior to initiating APR-246 treatment due to Investigator's decision.	101 Participants n=8 Participants • 36 patients were enrolled in the Phase Ib study. One patient from the 67.5 mg/kg dose cohort was withdrawn from the study prior to initiating APR-246 treatment due to Investigator's decision.
Age, Continuous	63 years n=5 Participants	62 years n=7 Participants	64.5 years n=5 Participants	61 years n=4 Participants	64 years n=21 Participants	62 years n=8 Participants
Sex: Female, Male Female	9 Participants n=5 Participants	6 Participants n=7 Participants	20 Participants n=5 Participants	105 Participants n=4 Participants	106 Participants n=21 Participants	246 Participants n=8 Participants
Sex: Female, Male Male	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=8 Participants
Race (NIH/OMB) American Indian or Alaska Native	0 Participants n=5 Participants • One patient in the 67.5 mg/kg dose cohort (Patient 441-P016) did not meet the eligibility criteria (Exclusion criteria). The eligibility issue for this patient was discovered after the patient had commenced treatment. However, the patient continued the study treatment since it would have been unethical to withdraw the patient from the study.	0 Participants n=7 Participants • One patient in the 67.5 mg/kg dose cohort (Patient 441-P016) did not meet the eligibility criteria (Exclusion criteria). The eligibility issue for this patient was discovered after the patient had commenced treatment. However, the patient continued the study treatment since it would have been unethical to withdraw the patient from the study.	0 Participants n=5 Participants • One patient in the 67.5 mg/kg dose cohort (Patient 441-P016) did not meet the eligibility criteria (Exclusion criteria). The eligibility issue for this patient was discovered after the patient had commenced treatment. However, the patient continued the study treatment since it would have been unethical to withdraw the patient from the study.	0 Participants n=4 Participants • One patient in the 67.5 mg/kg dose cohort (Patient 441-P016) did not meet the eligibility criteria (Exclusion criteria). The eligibility issue for this patient was discovered after the patient had commenced treatment. However, the patient continued the study treatment since it would have been unethical to withdraw the patient from the study.	0 Participants n=21 Participants • One patient in the 67.5 mg/kg dose cohort (Patient 441-P016) did not meet the eligibility criteria (Exclusion criteria). The eligibility issue for this patient was discovered after the patient had commenced treatment. However, the patient continued the study treatment since it would have been unethical to withdraw the patient from the study.	0 Participants n=8 Participants • One patient in the 67.5 mg/kg dose cohort (Patient 441-P016) did not meet the eligibility criteria (Exclusion criteria). The eligibility issue for this patient was discovered after the patient had commenced treatment. However, the patient continued the study treatment since it would have been unethical to withdraw the patient from the study.
Race (NIH/OMB) Asian	0 Participants n=5 Participants • One patient in the 67.5 mg/kg dose cohort (Patient 441-P016) did not meet the eligibility criteria (Exclusion criteria). The eligibility issue for this patient was discovered after the patient had commenced treatment. However, the patient continued the study treatment since it would have been unethical to withdraw the patient from the study.	0 Participants n=7 Participants • One patient in the 67.5 mg/kg dose cohort (Patient 441-P016) did not meet the eligibility criteria (Exclusion criteria). The eligibility issue for this patient was discovered after the patient had commenced treatment. However, the patient continued the study treatment since it would have been unethical to withdraw the patient from the study.	3 Participants n=5 Participants • One patient in the 67.5 mg/kg dose cohort (Patient 441-P016) did not meet the eligibility criteria (Exclusion criteria). The eligibility issue for this patient was discovered after the patient had commenced treatment. However, the patient continued the study treatment since it would have been unethical to withdraw the patient from the study.	3 Participants n=4 Participants • One patient in the 67.5 mg/kg dose cohort (Patient 441-P016) did not meet the eligibility criteria (Exclusion criteria). The eligibility issue for this patient was discovered after the patient had commenced treatment. However, the patient continued the study treatment since it would have been unethical to withdraw the patient from the study.	2 Participants n=21 Participants • One patient in the 67.5 mg/kg dose cohort (Patient 441-P016) did not meet the eligibility criteria (Exclusion criteria). The eligibility issue for this patient was discovered after the patient had commenced treatment. However, the patient continued the study treatment since it would have been unethical to withdraw the patient from the study.	8 Participants n=8 Participants • One patient in the 67.5 mg/kg dose cohort (Patient 441-P016) did not meet the eligibility criteria (Exclusion criteria). The eligibility issue for this patient was discovered after the patient had commenced treatment. However, the patient continued the study treatment since it would have been unethical to withdraw the patient from the study.
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants n=5 Participants • One patient in the 67.5 mg/kg dose cohort (Patient 441-P016) did not meet the eligibility criteria (Exclusion criteria). The eligibility issue for this patient was discovered after the patient had commenced treatment. However, the patient continued the study treatment since it would have been unethical to withdraw the patient from the study.	0 Participants n=7 Participants • One patient in the 67.5 mg/kg dose cohort (Patient 441-P016) did not meet the eligibility criteria (Exclusion criteria). The eligibility issue for this patient was discovered after the patient had commenced treatment. However, the patient continued the study treatment since it would have been unethical to withdraw the patient from the study.	0 Participants n=5 Participants • One patient in the 67.5 mg/kg dose cohort (Patient 441-P016) did not meet the eligibility criteria (Exclusion criteria). The eligibility issue for this patient was discovered after the patient had commenced treatment. However, the patient continued the study treatment since it would have been unethical to withdraw the patient from the study.	0 Participants n=4 Participants • One patient in the 67.5 mg/kg dose cohort (Patient 441-P016) did not meet the eligibility criteria (Exclusion criteria). The eligibility issue for this patient was discovered after the patient had commenced treatment. However, the patient continued the study treatment since it would have been unethical to withdraw the patient from the study.	0 Participants n=21 Participants • One patient in the 67.5 mg/kg dose cohort (Patient 441-P016) did not meet the eligibility criteria (Exclusion criteria). The eligibility issue for this patient was discovered after the patient had commenced treatment. However, the patient continued the study treatment since it would have been unethical to withdraw the patient from the study.	0 Participants n=8 Participants • One patient in the 67.5 mg/kg dose cohort (Patient 441-P016) did not meet the eligibility criteria (Exclusion criteria). The eligibility issue for this patient was discovered after the patient had commenced treatment. However, the patient continued the study treatment since it would have been unethical to withdraw the patient from the study.
Race (NIH/OMB) Black or African American	0 Participants n=5 Participants • One patient in the 67.5 mg/kg dose cohort (Patient 441-P016) did not meet the eligibility criteria (Exclusion criteria). The eligibility issue for this patient was discovered after the patient had commenced treatment. However, the patient continued the study treatment since it would have been unethical to withdraw the patient from the study.	0 Participants n=7 Participants • One patient in the 67.5 mg/kg dose cohort (Patient 441-P016) did not meet the eligibility criteria (Exclusion criteria). The eligibility issue for this patient was discovered after the patient had commenced treatment. However, the patient continued the study treatment since it would have been unethical to withdraw the patient from the study.	0 Participants n=5 Participants • One patient in the 67.5 mg/kg dose cohort (Patient 441-P016) did not meet the eligibility criteria (Exclusion criteria). The eligibility issue for this patient was discovered after the patient had commenced treatment. However, the patient continued the study treatment since it would have been unethical to withdraw the patient from the study.	1 Participants n=4 Participants • One patient in the 67.5 mg/kg dose cohort (Patient 441-P016) did not meet the eligibility criteria (Exclusion criteria). The eligibility issue for this patient was discovered after the patient had commenced treatment. However, the patient continued the study treatment since it would have been unethical to withdraw the patient from the study.	1 Participants n=21 Participants • One patient in the 67.5 mg/kg dose cohort (Patient 441-P016) did not meet the eligibility criteria (Exclusion criteria). The eligibility issue for this patient was discovered after the patient had commenced treatment. However, the patient continued the study treatment since it would have been unethical to withdraw the patient from the study.	2 Participants n=8 Participants • One patient in the 67.5 mg/kg dose cohort (Patient 441-P016) did not meet the eligibility criteria (Exclusion criteria). The eligibility issue for this patient was discovered after the patient had commenced treatment. However, the patient continued the study treatment since it would have been unethical to withdraw the patient from the study.
Race (NIH/OMB) White	9 Participants n=5 Participants • One patient in the 67.5 mg/kg dose cohort (Patient 441-P016) did not meet the eligibility criteria (Exclusion criteria). The eligibility issue for this patient was discovered after the patient had commenced treatment. However, the patient continued the study treatment since it would have been unethical to withdraw the patient from the study.	6 Participants n=7 Participants • One patient in the 67.5 mg/kg dose cohort (Patient 441-P016) did not meet the eligibility criteria (Exclusion criteria). The eligibility issue for this patient was discovered after the patient had commenced treatment. However, the patient continued the study treatment since it would have been unethical to withdraw the patient from the study.	17 Participants n=5 Participants • One patient in the 67.5 mg/kg dose cohort (Patient 441-P016) did not meet the eligibility criteria (Exclusion criteria). The eligibility issue for this patient was discovered after the patient had commenced treatment. However, the patient continued the study treatment since it would have been unethical to withdraw the patient from the study.	88 Participants n=4 Participants • One patient in the 67.5 mg/kg dose cohort (Patient 441-P016) did not meet the eligibility criteria (Exclusion criteria). The eligibility issue for this patient was discovered after the patient had commenced treatment. However, the patient continued the study treatment since it would have been unethical to withdraw the patient from the study.	81 Participants n=21 Participants • One patient in the 67.5 mg/kg dose cohort (Patient 441-P016) did not meet the eligibility criteria (Exclusion criteria). The eligibility issue for this patient was discovered after the patient had commenced treatment. However, the patient continued the study treatment since it would have been unethical to withdraw the patient from the study.	201 Participants n=8 Participants • One patient in the 67.5 mg/kg dose cohort (Patient 441-P016) did not meet the eligibility criteria (Exclusion criteria). The eligibility issue for this patient was discovered after the patient had commenced treatment. However, the patient continued the study treatment since it would have been unethical to withdraw the patient from the study.
Race (NIH/OMB) More than one race	0 Participants n=5 Participants • One patient in the 67.5 mg/kg dose cohort (Patient 441-P016) did not meet the eligibility criteria (Exclusion criteria). The eligibility issue for this patient was discovered after the patient had commenced treatment. However, the patient continued the study treatment since it would have been unethical to withdraw the patient from the study.	0 Participants n=7 Participants • One patient in the 67.5 mg/kg dose cohort (Patient 441-P016) did not meet the eligibility criteria (Exclusion criteria). The eligibility issue for this patient was discovered after the patient had commenced treatment. However, the patient continued the study treatment since it would have been unethical to withdraw the patient from the study.	0 Participants n=5 Participants • One patient in the 67.5 mg/kg dose cohort (Patient 441-P016) did not meet the eligibility criteria (Exclusion criteria). The eligibility issue for this patient was discovered after the patient had commenced treatment. However, the patient continued the study treatment since it would have been unethical to withdraw the patient from the study.	0 Participants n=4 Participants • One patient in the 67.5 mg/kg dose cohort (Patient 441-P016) did not meet the eligibility criteria (Exclusion criteria). The eligibility issue for this patient was discovered after the patient had commenced treatment. However, the patient continued the study treatment since it would have been unethical to withdraw the patient from the study.	0 Participants n=21 Participants • One patient in the 67.5 mg/kg dose cohort (Patient 441-P016) did not meet the eligibility criteria (Exclusion criteria). The eligibility issue for this patient was discovered after the patient had commenced treatment. However, the patient continued the study treatment since it would have been unethical to withdraw the patient from the study.	0 Participants n=8 Participants • One patient in the 67.5 mg/kg dose cohort (Patient 441-P016) did not meet the eligibility criteria (Exclusion criteria). The eligibility issue for this patient was discovered after the patient had commenced treatment. However, the patient continued the study treatment since it would have been unethical to withdraw the patient from the study.
Race (NIH/OMB) Unknown or Not Reported	0 Participants n=5 Participants • One patient in the 67.5 mg/kg dose cohort (Patient 441-P016) did not meet the eligibility criteria (Exclusion criteria). The eligibility issue for this patient was discovered after the patient had commenced treatment. However, the patient continued the study treatment since it would have been unethical to withdraw the patient from the study.	0 Participants n=7 Participants • One patient in the 67.5 mg/kg dose cohort (Patient 441-P016) did not meet the eligibility criteria (Exclusion criteria). The eligibility issue for this patient was discovered after the patient had commenced treatment. However, the patient continued the study treatment since it would have been unethical to withdraw the patient from the study.	0 Participants n=5 Participants • One patient in the 67.5 mg/kg dose cohort (Patient 441-P016) did not meet the eligibility criteria (Exclusion criteria). The eligibility issue for this patient was discovered after the patient had commenced treatment. However, the patient continued the study treatment since it would have been unethical to withdraw the patient from the study.	13 Participants n=4 Participants • One patient in the 67.5 mg/kg dose cohort (Patient 441-P016) did not meet the eligibility criteria (Exclusion criteria). The eligibility issue for this patient was discovered after the patient had commenced treatment. However, the patient continued the study treatment since it would have been unethical to withdraw the patient from the study.	22 Participants n=21 Participants • One patient in the 67.5 mg/kg dose cohort (Patient 441-P016) did not meet the eligibility criteria (Exclusion criteria). The eligibility issue for this patient was discovered after the patient had commenced treatment. However, the patient continued the study treatment since it would have been unethical to withdraw the patient from the study.	35 Participants n=8 Participants • One patient in the 67.5 mg/kg dose cohort (Patient 441-P016) did not meet the eligibility criteria (Exclusion criteria). The eligibility issue for this patient was discovered after the patient had commenced treatment. However, the patient continued the study treatment since it would have been unethical to withdraw the patient from the study.
Region of Enrollment Netherlands	0 participants n=5 Participants • One patient in the 67.5 mg/kg dose cohort (Patient 441-P016) did not meet the eligibility criteria (Exclusion criteria). The eligibility issue for this patient was discovered after the patient had commenced treatment. However, the patient continued the study treatment since it would have been unethical to withdraw the patient from the study.	0 participants n=7 Participants • One patient in the 67.5 mg/kg dose cohort (Patient 441-P016) did not meet the eligibility criteria (Exclusion criteria). The eligibility issue for this patient was discovered after the patient had commenced treatment. However, the patient continued the study treatment since it would have been unethical to withdraw the patient from the study.	0 participants n=5 Participants • One patient in the 67.5 mg/kg dose cohort (Patient 441-P016) did not meet the eligibility criteria (Exclusion criteria). The eligibility issue for this patient was discovered after the patient had commenced treatment. However, the patient continued the study treatment since it would have been unethical to withdraw the patient from the study.	12 participants n=4 Participants • One patient in the 67.5 mg/kg dose cohort (Patient 441-P016) did not meet the eligibility criteria (Exclusion criteria). The eligibility issue for this patient was discovered after the patient had commenced treatment. However, the patient continued the study treatment since it would have been unethical to withdraw the patient from the study.	2 participants n=21 Participants • One patient in the 67.5 mg/kg dose cohort (Patient 441-P016) did not meet the eligibility criteria (Exclusion criteria). The eligibility issue for this patient was discovered after the patient had commenced treatment. However, the patient continued the study treatment since it would have been unethical to withdraw the patient from the study.	14 participants n=8 Participants • One patient in the 67.5 mg/kg dose cohort (Patient 441-P016) did not meet the eligibility criteria (Exclusion criteria). The eligibility issue for this patient was discovered after the patient had commenced treatment. However, the patient continued the study treatment since it would have been unethical to withdraw the patient from the study.
Region of Enrollment Sweden	0 participants n=5 Participants • One patient in the 67.5 mg/kg dose cohort (Patient 441-P016) did not meet the eligibility criteria (Exclusion criteria). The eligibility issue for this patient was discovered after the patient had commenced treatment. However, the patient continued the study treatment since it would have been unethical to withdraw the patient from the study.	0 participants n=7 Participants • One patient in the 67.5 mg/kg dose cohort (Patient 441-P016) did not meet the eligibility criteria (Exclusion criteria). The eligibility issue for this patient was discovered after the patient had commenced treatment. However, the patient continued the study treatment since it would have been unethical to withdraw the patient from the study.	0 participants n=5 Participants • One patient in the 67.5 mg/kg dose cohort (Patient 441-P016) did not meet the eligibility criteria (Exclusion criteria). The eligibility issue for this patient was discovered after the patient had commenced treatment. However, the patient continued the study treatment since it would have been unethical to withdraw the patient from the study.	1 participants n=4 Participants • One patient in the 67.5 mg/kg dose cohort (Patient 441-P016) did not meet the eligibility criteria (Exclusion criteria). The eligibility issue for this patient was discovered after the patient had commenced treatment. However, the patient continued the study treatment since it would have been unethical to withdraw the patient from the study.	3 participants n=21 Participants • One patient in the 67.5 mg/kg dose cohort (Patient 441-P016) did not meet the eligibility criteria (Exclusion criteria). The eligibility issue for this patient was discovered after the patient had commenced treatment. However, the patient continued the study treatment since it would have been unethical to withdraw the patient from the study.	4 participants n=8 Participants • One patient in the 67.5 mg/kg dose cohort (Patient 441-P016) did not meet the eligibility criteria (Exclusion criteria). The eligibility issue for this patient was discovered after the patient had commenced treatment. However, the patient continued the study treatment since it would have been unethical to withdraw the patient from the study.
Region of Enrollment Belgium	2 participants n=5 Participants • One patient in the 67.5 mg/kg dose cohort (Patient 441-P016) did not meet the eligibility criteria (Exclusion criteria). The eligibility issue for this patient was discovered after the patient had commenced treatment. However, the patient continued the study treatment since it would have been unethical to withdraw the patient from the study.	1 participants n=7 Participants • One patient in the 67.5 mg/kg dose cohort (Patient 441-P016) did not meet the eligibility criteria (Exclusion criteria). The eligibility issue for this patient was discovered after the patient had commenced treatment. However, the patient continued the study treatment since it would have been unethical to withdraw the patient from the study.	4 participants n=5 Participants • One patient in the 67.5 mg/kg dose cohort (Patient 441-P016) did not meet the eligibility criteria (Exclusion criteria). The eligibility issue for this patient was discovered after the patient had commenced treatment. However, the patient continued the study treatment since it would have been unethical to withdraw the patient from the study.	10 participants n=4 Participants • One patient in the 67.5 mg/kg dose cohort (Patient 441-P016) did not meet the eligibility criteria (Exclusion criteria). The eligibility issue for this patient was discovered after the patient had commenced treatment. However, the patient continued the study treatment since it would have been unethical to withdraw the patient from the study.	10 participants n=21 Participants • One patient in the 67.5 mg/kg dose cohort (Patient 441-P016) did not meet the eligibility criteria (Exclusion criteria). The eligibility issue for this patient was discovered after the patient had commenced treatment. However, the patient continued the study treatment since it would have been unethical to withdraw the patient from the study.	27 participants n=8 Participants • One patient in the 67.5 mg/kg dose cohort (Patient 441-P016) did not meet the eligibility criteria (Exclusion criteria). The eligibility issue for this patient was discovered after the patient had commenced treatment. However, the patient continued the study treatment since it would have been unethical to withdraw the patient from the study.
Region of Enrollment United States	0 participants n=5 Participants • One patient in the 67.5 mg/kg dose cohort (Patient 441-P016) did not meet the eligibility criteria (Exclusion criteria). The eligibility issue for this patient was discovered after the patient had commenced treatment. However, the patient continued the study treatment since it would have been unethical to withdraw the patient from the study.	0 participants n=7 Participants • One patient in the 67.5 mg/kg dose cohort (Patient 441-P016) did not meet the eligibility criteria (Exclusion criteria). The eligibility issue for this patient was discovered after the patient had commenced treatment. However, the patient continued the study treatment since it would have been unethical to withdraw the patient from the study.	0 participants n=5 Participants • One patient in the 67.5 mg/kg dose cohort (Patient 441-P016) did not meet the eligibility criteria (Exclusion criteria). The eligibility issue for this patient was discovered after the patient had commenced treatment. However, the patient continued the study treatment since it would have been unethical to withdraw the patient from the study.	17 participants n=4 Participants • One patient in the 67.5 mg/kg dose cohort (Patient 441-P016) did not meet the eligibility criteria (Exclusion criteria). The eligibility issue for this patient was discovered after the patient had commenced treatment. However, the patient continued the study treatment since it would have been unethical to withdraw the patient from the study.	20 participants n=21 Participants • One patient in the 67.5 mg/kg dose cohort (Patient 441-P016) did not meet the eligibility criteria (Exclusion criteria). The eligibility issue for this patient was discovered after the patient had commenced treatment. However, the patient continued the study treatment since it would have been unethical to withdraw the patient from the study.	37 participants n=8 Participants • One patient in the 67.5 mg/kg dose cohort (Patient 441-P016) did not meet the eligibility criteria (Exclusion criteria). The eligibility issue for this patient was discovered after the patient had commenced treatment. However, the patient continued the study treatment since it would have been unethical to withdraw the patient from the study.
Region of Enrollment United Kingdom	7 participants n=5 Participants • One patient in the 67.5 mg/kg dose cohort (Patient 441-P016) did not meet the eligibility criteria (Exclusion criteria). The eligibility issue for this patient was discovered after the patient had commenced treatment. However, the patient continued the study treatment since it would have been unethical to withdraw the patient from the study.	5 participants n=7 Participants • One patient in the 67.5 mg/kg dose cohort (Patient 441-P016) did not meet the eligibility criteria (Exclusion criteria). The eligibility issue for this patient was discovered after the patient had commenced treatment. However, the patient continued the study treatment since it would have been unethical to withdraw the patient from the study.	16 participants n=5 Participants • One patient in the 67.5 mg/kg dose cohort (Patient 441-P016) did not meet the eligibility criteria (Exclusion criteria). The eligibility issue for this patient was discovered after the patient had commenced treatment. However, the patient continued the study treatment since it would have been unethical to withdraw the patient from the study.	33 participants n=4 Participants • One patient in the 67.5 mg/kg dose cohort (Patient 441-P016) did not meet the eligibility criteria (Exclusion criteria). The eligibility issue for this patient was discovered after the patient had commenced treatment. However, the patient continued the study treatment since it would have been unethical to withdraw the patient from the study.	19 participants n=21 Participants • One patient in the 67.5 mg/kg dose cohort (Patient 441-P016) did not meet the eligibility criteria (Exclusion criteria). The eligibility issue for this patient was discovered after the patient had commenced treatment. However, the patient continued the study treatment since it would have been unethical to withdraw the patient from the study.	80 participants n=8 Participants • One patient in the 67.5 mg/kg dose cohort (Patient 441-P016) did not meet the eligibility criteria (Exclusion criteria). The eligibility issue for this patient was discovered after the patient had commenced treatment. However, the patient continued the study treatment since it would have been unethical to withdraw the patient from the study.
Region of Enrollment France	0 participants n=5 Participants • One patient in the 67.5 mg/kg dose cohort (Patient 441-P016) did not meet the eligibility criteria (Exclusion criteria). The eligibility issue for this patient was discovered after the patient had commenced treatment. However, the patient continued the study treatment since it would have been unethical to withdraw the patient from the study.	0 participants n=7 Participants • One patient in the 67.5 mg/kg dose cohort (Patient 441-P016) did not meet the eligibility criteria (Exclusion criteria). The eligibility issue for this patient was discovered after the patient had commenced treatment. However, the patient continued the study treatment since it would have been unethical to withdraw the patient from the study.	0 participants n=5 Participants • One patient in the 67.5 mg/kg dose cohort (Patient 441-P016) did not meet the eligibility criteria (Exclusion criteria). The eligibility issue for this patient was discovered after the patient had commenced treatment. However, the patient continued the study treatment since it would have been unethical to withdraw the patient from the study.	12 participants n=4 Participants • One patient in the 67.5 mg/kg dose cohort (Patient 441-P016) did not meet the eligibility criteria (Exclusion criteria). The eligibility issue for this patient was discovered after the patient had commenced treatment. However, the patient continued the study treatment since it would have been unethical to withdraw the patient from the study.	20 participants n=21 Participants • One patient in the 67.5 mg/kg dose cohort (Patient 441-P016) did not meet the eligibility criteria (Exclusion criteria). The eligibility issue for this patient was discovered after the patient had commenced treatment. However, the patient continued the study treatment since it would have been unethical to withdraw the patient from the study.	32 participants n=8 Participants • One patient in the 67.5 mg/kg dose cohort (Patient 441-P016) did not meet the eligibility criteria (Exclusion criteria). The eligibility issue for this patient was discovered after the patient had commenced treatment. However, the patient continued the study treatment since it would have been unethical to withdraw the patient from the study.
Region of Enrollment Germany	0 participants n=5 Participants • One patient in the 67.5 mg/kg dose cohort (Patient 441-P016) did not meet the eligibility criteria (Exclusion criteria). The eligibility issue for this patient was discovered after the patient had commenced treatment. However, the patient continued the study treatment since it would have been unethical to withdraw the patient from the study.	0 participants n=7 Participants • One patient in the 67.5 mg/kg dose cohort (Patient 441-P016) did not meet the eligibility criteria (Exclusion criteria). The eligibility issue for this patient was discovered after the patient had commenced treatment. However, the patient continued the study treatment since it would have been unethical to withdraw the patient from the study.	0 participants n=5 Participants • One patient in the 67.5 mg/kg dose cohort (Patient 441-P016) did not meet the eligibility criteria (Exclusion criteria). The eligibility issue for this patient was discovered after the patient had commenced treatment. However, the patient continued the study treatment since it would have been unethical to withdraw the patient from the study.	1 participants n=4 Participants • One patient in the 67.5 mg/kg dose cohort (Patient 441-P016) did not meet the eligibility criteria (Exclusion criteria). The eligibility issue for this patient was discovered after the patient had commenced treatment. However, the patient continued the study treatment since it would have been unethical to withdraw the patient from the study.	10 participants n=21 Participants • One patient in the 67.5 mg/kg dose cohort (Patient 441-P016) did not meet the eligibility criteria (Exclusion criteria). The eligibility issue for this patient was discovered after the patient had commenced treatment. However, the patient continued the study treatment since it would have been unethical to withdraw the patient from the study.	11 participants n=8 Participants • One patient in the 67.5 mg/kg dose cohort (Patient 441-P016) did not meet the eligibility criteria (Exclusion criteria). The eligibility issue for this patient was discovered after the patient had commenced treatment. However, the patient continued the study treatment since it would have been unethical to withdraw the patient from the study.
Region of Enrollment Spain	0 participants n=5 Participants • One patient in the 67.5 mg/kg dose cohort (Patient 441-P016) did not meet the eligibility criteria (Exclusion criteria). The eligibility issue for this patient was discovered after the patient had commenced treatment. However, the patient continued the study treatment since it would have been unethical to withdraw the patient from the study.	0 participants n=7 Participants • One patient in the 67.5 mg/kg dose cohort (Patient 441-P016) did not meet the eligibility criteria (Exclusion criteria). The eligibility issue for this patient was discovered after the patient had commenced treatment. However, the patient continued the study treatment since it would have been unethical to withdraw the patient from the study.	0 participants n=5 Participants • One patient in the 67.5 mg/kg dose cohort (Patient 441-P016) did not meet the eligibility criteria (Exclusion criteria). The eligibility issue for this patient was discovered after the patient had commenced treatment. However, the patient continued the study treatment since it would have been unethical to withdraw the patient from the study.	19 participants n=4 Participants • One patient in the 67.5 mg/kg dose cohort (Patient 441-P016) did not meet the eligibility criteria (Exclusion criteria). The eligibility issue for this patient was discovered after the patient had commenced treatment. However, the patient continued the study treatment since it would have been unethical to withdraw the patient from the study.	22 participants n=21 Participants • One patient in the 67.5 mg/kg dose cohort (Patient 441-P016) did not meet the eligibility criteria (Exclusion criteria). The eligibility issue for this patient was discovered after the patient had commenced treatment. However, the patient continued the study treatment since it would have been unethical to withdraw the patient from the study.	41 participants n=8 Participants • One patient in the 67.5 mg/kg dose cohort (Patient 441-P016) did not meet the eligibility criteria (Exclusion criteria). The eligibility issue for this patient was discovered after the patient had commenced treatment. However, the patient continued the study treatment since it would have been unethical to withdraw the patient from the study.

PRIMARY outcome

Timeframe: Until the end of the first treatment cycle, i.e., Day 28

DLT: Hematological and non-hematological toxicities according to grade/days stated in the protocol.

Outcome measures

Measure	Phase Ib. APR-246 (35mg/kg) + Carboplatin/PLD. n=9 Participants Dose escalation of APR-246. APR-246: Intravenous infusion. Carboplatin and Pegylated Liposomal Doxorubicin Hydrochloride (PLD): Intravenous infusion.	Phase Ib. APR-246 (50mg/kg) + Carboplatin/PLD. n=6 Participants Dose escalation of APR-246. APR-246: Intravenous infusion. Carboplatin and Pegylated Liposomal Doxorubicin Hydrochloride (PLD): Intravenous infusion.	Phase Ib. APR-246 (67.5mg/kg) + Carboplatin/PLD. n=20 Participants Dose escalation of APR-246. APR-246: Intravenous infusion. Carboplatin and Pegylated Liposomal Doxorubicin Hydrochloride (PLD): Intravenous infusion.	Phase II: Arm A. APR-246 + Carboplatin/PLD. Experimental APR-246: Intravenous infusion. Carboplatin and Pegylated Liposomal Doxorubicin Hydrochloride (PLD): Intravenous infusion.	Phase II: Arm B. Carboplatin/PLD. Active Comparator Carboplatin and Pegylated Liposomal Doxorubicin Hydrochloride (PLD): Intravenous infusion.
Phase Ib: Dose-limiting Toxicities (DLT) (See Description) of Combined APR-246 and Carboplatin/PLD Regimen	0 Participants	1 Participants	0 Participants	—	—

PRIMARY outcome

Timeframe: Up to 24 months

Population: Ph Ib = Efficacy Evaluable Ph II = ITT

Phase Ib: Progression-free Survival is calculated from date of enrollment to the date of disease progression or death due to any cause, whichever occurs first. Symptomatic deterioration is not considered PD. For a patient without evidence of disease progression or death, Progression-free survival will be censored at the date of last evaluable tumor assessment. Patients with no evaluable tumor assessments will be censored at the date of first study drug administration.

Phase II: Progression-free survival (PFS) based on Blinded Independent Central Review (BICR) is the primary endpoint and is defined as the number of days from the date of randomization to the date of objective disease progression or relapse (according to RECIST v1.1 only) or death due to any cause, whichever occurs first. If neither event occurs, PFS is censored at the date of the last evaluable tumor assessment. Symptomatic deterioration is not considered objective disease progression.

Outcome measures

Measure	Phase Ib. APR-246 (35mg/kg) + Carboplatin/PLD. n=7 Participants Dose escalation of APR-246. APR-246: Intravenous infusion. Carboplatin and Pegylated Liposomal Doxorubicin Hydrochloride (PLD): Intravenous infusion.	Phase Ib. APR-246 (50mg/kg) + Carboplatin/PLD. n=4 Participants Dose escalation of APR-246. APR-246: Intravenous infusion. Carboplatin and Pegylated Liposomal Doxorubicin Hydrochloride (PLD): Intravenous infusion.	Phase Ib. APR-246 (67.5mg/kg) + Carboplatin/PLD. n=19 Participants Dose escalation of APR-246. APR-246: Intravenous infusion. Carboplatin and Pegylated Liposomal Doxorubicin Hydrochloride (PLD): Intravenous infusion.	Phase II: Arm A. APR-246 + Carboplatin/PLD. n=105 Participants Experimental APR-246: Intravenous infusion. Carboplatin and Pegylated Liposomal Doxorubicin Hydrochloride (PLD): Intravenous infusion.	Phase II: Arm B. Carboplatin/PLD. n=106 Participants Active Comparator Carboplatin and Pegylated Liposomal Doxorubicin Hydrochloride (PLD): Intravenous infusion.
Phase Ib and II: Progression Free Survival (PFS)	330 days Interval 280.0 to 444.0	277.5 days Interval 175.0 to 375.0	313 days Interval 98.0 to 590.0	283 days Interval 240.0 to 314.0	295 days Interval 259.0 to 335.0

SECONDARY outcome

Timeframe: Up to 24 months

Population: Phase Ib = Efficacy Evaluable population Phase II = ITT population

Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.

Outcome measures

Measure	Phase Ib. APR-246 (35mg/kg) + Carboplatin/PLD. n=7 Participants Dose escalation of APR-246. APR-246: Intravenous infusion. Carboplatin and Pegylated Liposomal Doxorubicin Hydrochloride (PLD): Intravenous infusion.	Phase Ib. APR-246 (50mg/kg) + Carboplatin/PLD. n=4 Participants Dose escalation of APR-246. APR-246: Intravenous infusion. Carboplatin and Pegylated Liposomal Doxorubicin Hydrochloride (PLD): Intravenous infusion.	Phase Ib. APR-246 (67.5mg/kg) + Carboplatin/PLD. n=19 Participants Dose escalation of APR-246. APR-246: Intravenous infusion. Carboplatin and Pegylated Liposomal Doxorubicin Hydrochloride (PLD): Intravenous infusion.	Phase II: Arm A. APR-246 + Carboplatin/PLD. n=105 Participants Experimental APR-246: Intravenous infusion. Carboplatin and Pegylated Liposomal Doxorubicin Hydrochloride (PLD): Intravenous infusion.	Phase II: Arm B. Carboplatin/PLD. n=106 Participants Active Comparator Carboplatin and Pegylated Liposomal Doxorubicin Hydrochloride (PLD): Intravenous infusion.
Phase Ib and Phase II: Overall Response Rate (RR) Complete Response (CR)	1 Participants	0 Participants	2 Participants	10 Participants	3 Participants
Phase Ib and Phase II: Overall Response Rate (RR) Partial response (PR)	5 Participants	1 Participants	9 Participants	42 Participants	50 Participants
Phase Ib and Phase II: Overall Response Rate (RR) Stable Disease (SD)	1 Participants	3 Participants	5 Participants	27 Participants	37 Participants
Phase Ib and Phase II: Overall Response Rate (RR) Progressive Disease (PD)	0 Participants	0 Participants	0 Participants	15 Participants	5 Participants
Phase Ib and Phase II: Overall Response Rate (RR) Not Evaluable (NE)	0 Participants	0 Participants	3 Participants	11 Participants	11 Participants

Adverse Events

Phase Ib. APR-246 (35mg/kg) + Carboplatin/PLD.

Serious events: 3 serious events

Other events: 9 other events

Deaths: 4 deaths

Phase Ib. APR-246 (50mg/kg) + Carboplatin/PLD.

Serious events: 4 serious events

Other events: 6 other events

Deaths: 3 deaths

Phase Ib. APR-246 (67.5mg/kg) + Carboplatin/PLD.

Serious events: 12 serious events

Other events: 20 other events

Deaths: 10 deaths

Phase II: Arm A. APR-246 + Carboplatin/PLD.

Serious events: 31 serious events

Other events: 99 other events

Deaths: 0 deaths

Phase II: Arm B. Carboplatin/PLD.

Serious events: 17 serious events

Other events: 101 other events

Deaths: 2 deaths

Serious adverse events

Measure	Phase Ib. APR-246 (35mg/kg) + Carboplatin/PLD. n=9 participants at risk Dose escalation of APR-246. APR-246: Intravenous infusion. Carboplatin and Pegylated Liposomal Doxorubicin Hydrochloride (PLD): Intravenous infusion. All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg	Phase Ib. APR-246 (50mg/kg) + Carboplatin/PLD. n=6 participants at risk Dose escalation of APR-246. APR-246: Intravenous infusion. Carboplatin and Pegylated Liposomal Doxorubicin Hydrochloride (PLD): Intravenous infusion. All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg	Phase Ib. APR-246 (67.5mg/kg) + Carboplatin/PLD. n=20 participants at risk Dose escalation of APR-246. APR-246: Intravenous infusion. Carboplatin and Pegylated Liposomal Doxorubicin Hydrochloride (PLD): Intravenous infusion. All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg	Phase II: Arm A. APR-246 + Carboplatin/PLD. n=99 participants at risk Experimental APR-246: Intravenous infusion. Carboplatin and Pegylated Liposomal Doxorubicin Hydrochloride (PLD): Intravenous infusion.	Phase II: Arm B. Carboplatin/PLD. n=101 participants at risk Active Comparator Carboplatin and Pegylated Liposomal Doxorubicin Hydrochloride (PLD): Intravenous infusion.
Gastrointestinal disorders Small intestinal obstruction	0.00% 0/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	10.0% 2/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	4.0% 4/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	4.0% 4/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Gastrointestinal disorders Nausea	0.00% 0/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	2.0% 2/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	2.0% 2/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Gastrointestinal disorders Vomitting	0.00% 0/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	30.0% 6/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	2.0% 2/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	2.0% 2/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Gastrointestinal disorders Abdominal pain	0.00% 0/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	1.0% 1/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	2.0% 2/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Gastrointestinal disorders Constipation	0.00% 0/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	2.0% 2/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Gastrointestinal disorders Large intestine perforation	0.00% 0/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	16.7% 1/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	2.0% 2/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Gastrointestinal disorders Diarrhoea	0.00% 0/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	5.0% 1/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	1.0% 1/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Gastrointestinal disorders Faecaloma	0.00% 0/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	1.0% 1/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Gastrointestinal disorders Ileus	0.00% 0/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	1.0% 1/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Gastrointestinal disorders Intestinal obstruction	0.00% 0/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	10.0% 2/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	1.0% 1/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Gastrointestinal disorders Large intestinal obstruction	0.00% 0/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	1.0% 1/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.99% 1/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Gastrointestinal disorders Small intestinal perforation	0.00% 0/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	1.0% 1/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Gastrointestinal disorders Stomatitis	0.00% 0/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	1.0% 1/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Infections and infestations Infectious pleural effusion	0.00% 0/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	1.0% 1/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.99% 1/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Infections and infestations Urinary tract infection	0.00% 0/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	1.0% 1/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.99% 1/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Infections and infestations Abdominal abscess	0.00% 0/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	1.0% 1/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Infections and infestations Bronchitis	0.00% 0/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	1.0% 1/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Infections and infestations Device related infection	11.1% 1/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	33.3% 2/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	15.0% 3/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.99% 1/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Infections and infestations Device related sepsis	11.1% 1/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	1.0% 1/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Infections and infestations Klebsiella infection	0.00% 0/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	1.0% 1/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Infections and infestations Lower respiratory tract infection	0.00% 0/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.99% 1/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Infections and infestations Pneumonia	0.00% 0/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	5.0% 1/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.99% 1/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Infections and infestations Upper respiratory tract infection	0.00% 0/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	1.0% 1/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Infections and infestations Viral upper respiratory tract infection	0.00% 0/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	1.0% 1/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Blood and lymphatic system disorders Thrombocytopenia	0.00% 0/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	16.7% 1/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	5.0% 1/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	4.0% 4/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.99% 1/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Blood and lymphatic system disorders Anaemia	0.00% 0/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	2.0% 2/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.99% 1/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Blood and lymphatic system disorders Febrile neutropenia	11.1% 1/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	5.0% 1/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.99% 1/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Blood and lymphatic system disorders Leukopenia	0.00% 0/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	1.0% 1/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Blood and lymphatic system disorders Neutropenia	0.00% 0/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.99% 1/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Nervous system disorders Dizziness	0.00% 0/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	5.0% 1/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	2.0% 2/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Nervous system disorders Ataxia	0.00% 0/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	1.0% 1/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Nervous system disorders Balance disorder	0.00% 0/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	1.0% 1/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Nervous system disorders Cerebral infarction	0.00% 0/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	1.0% 1/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Nervous system disorders Dysarthria	0.00% 0/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	1.0% 1/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Nervous system disorders Syncope	0.00% 0/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.99% 1/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
General disorders Malaise	0.00% 0/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	1.0% 1/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Nervous system disorders Transient ischaemic attack	0.00% 0/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.99% 1/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
General disorders Pyrexia	0.00% 0/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	5.0% 1/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	1.0% 1/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Respiratory, thoracic and mediastinal disorders Dyspnoea	0.00% 0/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	4.0% 4/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Respiratory, thoracic and mediastinal disorders Pleural effusion	0.00% 0/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	1.0% 1/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Respiratory, thoracic and mediastinal disorders Pulmonary embolism	0.00% 0/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	1.0% 1/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Metabolism and nutrition disorders Dehydration	0.00% 0/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	1.0% 1/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.99% 1/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Metabolism and nutrition disorders Decreased appetite	0.00% 0/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.99% 1/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Metabolism and nutrition disorders Hypomagnesaemia	0.00% 0/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	1.0% 1/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Renal and urinary disorders Renal impairment	0.00% 0/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	3.0% 3/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.99% 1/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
General disorders Asthenia	0.00% 0/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	1.0% 1/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
General disorders Injection site haemorrhage	0.00% 0/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	1.0% 1/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Cardiac disorders Cardiomyopathy	0.00% 0/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.99% 1/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Hepatobiliary disorders Drug-induced liver injury	0.00% 0/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	1.0% 1/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Injury, poisoning and procedural complications Lumbar vertebral fracture	0.00% 0/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.99% 1/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Injury, poisoning and procedural complications Thoracic vertebral fracture	0.00% 0/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.99% 1/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Investigations Alanine aminotransferase increased	0.00% 0/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	1.0% 1/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Investigations Aspartate aminotransferase increased	0.00% 0/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	1.0% 1/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Vascular disorders Peripheral artery stenosis	0.00% 0/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	1.0% 1/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Infections and infestations Infection	0.00% 0/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	16.7% 1/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	5.0% 1/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Infections and infestations Abdominal infection	0.00% 0/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	16.7% 1/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Infections and infestations Campylobacter infection	0.00% 0/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	5.0% 1/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Infections and infestations Enterocolitis infectious	11.1% 1/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Infections and infestations Escherichia infection	0.00% 0/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	5.0% 1/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Infections and infestations Influenza	0.00% 0/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	16.7% 1/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Infections and infestations Phlebitis infective	0.00% 0/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	5.0% 1/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Metabolism and nutrition disorders Hypocalcaemia	0.00% 0/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	5.0% 1/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Metabolism and nutrition disorders Hypokalaemia	0.00% 0/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	5.0% 1/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Reproductive system and breast disorders Vaginal hemorrhage	0.00% 0/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	16.7% 1/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.

Other adverse events

Measure	Phase Ib. APR-246 (35mg/kg) + Carboplatin/PLD. n=9 participants at risk Dose escalation of APR-246. APR-246: Intravenous infusion. Carboplatin and Pegylated Liposomal Doxorubicin Hydrochloride (PLD): Intravenous infusion. All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg	Phase Ib. APR-246 (50mg/kg) + Carboplatin/PLD. n=6 participants at risk Dose escalation of APR-246. APR-246: Intravenous infusion. Carboplatin and Pegylated Liposomal Doxorubicin Hydrochloride (PLD): Intravenous infusion. All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg	Phase Ib. APR-246 (67.5mg/kg) + Carboplatin/PLD. n=20 participants at risk Dose escalation of APR-246. APR-246: Intravenous infusion. Carboplatin and Pegylated Liposomal Doxorubicin Hydrochloride (PLD): Intravenous infusion. All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg	Phase II: Arm A. APR-246 + Carboplatin/PLD. n=99 participants at risk Experimental APR-246: Intravenous infusion. Carboplatin and Pegylated Liposomal Doxorubicin Hydrochloride (PLD): Intravenous infusion.	Phase II: Arm B. Carboplatin/PLD. n=101 participants at risk Active Comparator Carboplatin and Pegylated Liposomal Doxorubicin Hydrochloride (PLD): Intravenous infusion.
Gastrointestinal disorders Stomatitis	0.00% 0/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	20.0% 4/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	12.1% 12/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	10.9% 11/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Gastrointestinal disorders Nausea	88.9% 8/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	50.0% 3/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	80.0% 16/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	67.7% 67/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	56.4% 57/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Gastrointestinal disorders Vomitting	44.4% 4/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	33.3% 2/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	80.0% 16/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	42.4% 42/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	22.8% 23/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Gastrointestinal disorders Diarrhea	33.3% 3/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	66.7% 4/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	50.0% 10/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	12.1% 12/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	15.8% 16/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Gastrointestinal disorders Constipation	55.6% 5/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	50.0% 3/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	40.0% 8/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	36.4% 36/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	32.7% 33/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Gastrointestinal disorders Abdominal pain	33.3% 3/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	16.7% 1/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	30.0% 6/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	16.2% 16/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	15.8% 16/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Gastrointestinal disorders Abdominal pain lower	11.1% 1/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	33.3% 2/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	5.0% 1/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	3.0% 3/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	3.0% 3/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Gastrointestinal disorders Dyspepsia	11.1% 1/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	15.0% 3/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	8.1% 8/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	5.9% 6/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
General disorders Asthenia	0.00% 0/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	19.2% 19/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	21.8% 22/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
General disorders Fatigue	88.9% 8/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	83.3% 5/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	80.0% 16/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	47.5% 47/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	37.6% 38/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
General disorders Mucosal inflammation	44.4% 4/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	16.7% 1/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	25.0% 5/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	20.2% 20/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	21.8% 22/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
General disorders Pyrexia	0.00% 0/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	16.7% 1/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	30.0% 6/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	13.1% 13/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	9.9% 10/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
General disorders Device occlusion	22.2% 2/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	33.3% 2/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	10.0% 2/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	1.0% 1/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Nervous system disorders Dizziness	66.7% 6/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	50.0% 3/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	75.0% 15/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	42.4% 42/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	5.0% 5/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Nervous system disorders Headache	77.8% 7/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	50.0% 3/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	30.0% 6/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	16.2% 16/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	10.9% 11/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Nervous system disorders Dysgeusia	66.7% 6/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	50.0% 3/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	15.0% 3/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	3.0% 3/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	5.9% 6/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Nervous system disorders Tremor	11.1% 1/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	16.7% 1/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	15.0% 3/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	8.1% 8/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Nervous system disorders Neuropathy peripheral	0.00% 0/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	20.0% 4/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	11.1% 11/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	5.9% 6/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Blood and lymphatic system disorders Neutropenia	77.8% 7/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	100.0% 6/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	75.0% 15/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	56.6% 56/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	38.6% 39/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Blood and lymphatic system disorders Anemia	33.3% 3/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	50.0% 3/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	30.0% 6/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	31.3% 31/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	29.7% 30/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Blood and lymphatic system disorders Thrombocytopenia	33.3% 3/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	33.3% 2/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	30.0% 6/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	23.2% 23/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	13.9% 14/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Musculoskeletal and connective tissue disorders Back pain	33.3% 3/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	16.7% 1/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	25.0% 5/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	13.1% 13/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	6.9% 7/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Musculoskeletal and connective tissue disorders Arthralgia	22.2% 2/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	25.0% 5/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	10.1% 10/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	5.0% 5/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Musculoskeletal and connective tissue disorders Muscular weakness	22.2% 2/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	16.7% 1/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	20.0% 4/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	1.0% 1/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.99% 1/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Musculoskeletal and connective tissue disorders Muscle spasms	22.2% 2/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	16.7% 1/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	10.0% 2/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	2.0% 2/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	2.0% 2/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Infections and infestations Device related infection	11.1% 1/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	33.3% 2/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	15.0% 3/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	3.0% 3/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Infections and infestations Urinary tract infection	11.1% 1/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	20.0% 4/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	10.1% 10/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	17.8% 18/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Metabolism and nutrition disorders Decreased appetite	44.4% 4/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	16.7% 1/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	45.0% 9/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	19.2% 19/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	17.8% 18/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Metabolism and nutrition disorders Hypomagnesaemia	11.1% 1/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	16.7% 1/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	15.0% 3/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	12.1% 12/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	10.9% 11/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Skin and subcutaneous tissue disorders Palmar-plantar erythrodysaesthesia syndrome	44.4% 4/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	5.0% 1/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	11.1% 11/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	17.8% 18/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Skin and subcutaneous tissue disorders Rash	22.2% 2/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	20.0% 4/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	10.1% 10/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	11.9% 12/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Skin and subcutaneous tissue disorders Alopecia	0.00% 0/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	16.7% 1/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	20.0% 4/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	6.1% 6/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	5.9% 6/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Respiratory, thoracic and mediastinal disorders Cough	22.2% 2/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	15.0% 3/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	15.2% 15/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	5.9% 6/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Respiratory, thoracic and mediastinal disorders Oropharyngeal pain	11.1% 1/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	15.0% 3/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	2.0% 2/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Respiratory, thoracic and mediastinal disorders Dyspnoea	0.00% 0/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	15.0% 3/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	16.2% 16/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	4.0% 4/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Investigations Neutrophil count decreased	0.00% 0/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	5.0% 1/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	12.1% 12/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	10.9% 11/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Investigations Platelet count decreased	0.00% 0/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	11.1% 11/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	5.0% 5/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Gastrointestinal disorders Abdominal pain upper	0.00% 0/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	15.0% 3/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	5.1% 5/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	5.9% 6/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Gastrointestinal disorders Cheilitis	0.00% 0/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	10.0% 2/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Gastrointestinal disorders Small intestinal obstruction	0.00% 0/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	10.0% 2/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	4.0% 4/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	4.0% 4/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Gastrointestinal disorders Mouth ulceration	0.00% 0/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	5.0% 1/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	5.1% 5/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	5.0% 5/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Gastrointestinal disorders Abdominal distension	0.00% 0/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	5.0% 1/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	4.0% 4/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	5.0% 5/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Gastrointestinal disorders Gastrooesophageal reflux disease	0.00% 0/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	7.1% 7/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.99% 1/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
General disorders Chills	0.00% 0/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	15.0% 3/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	3.0% 3/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	2.0% 2/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
General disorders Infusion site erythema	0.00% 0/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	10.0% 2/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	2.0% 2/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.99% 1/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
General disorders Oedema peripheral	0.00% 0/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	10.0% 2/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	7.1% 7/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	3.0% 3/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
General disorders Malaise	0.00% 0/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	5.0% 1/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	5.1% 5/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	2.0% 2/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Nervous system disorders Dyskinesia	0.00% 0/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	15.0% 3/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	3.0% 3/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Nervous system disorders Hyperaesthesia	0.00% 0/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	10.0% 2/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	1.0% 1/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Nervous system disorders Somnolence	0.00% 0/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	10.0% 2/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	3.0% 3/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Nervous system disorders Paraesthesia	0.00% 0/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	8.1% 8/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	2.0% 2/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Nervous system disorders Peripheral sensory neuropathy	0.00% 0/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	5.0% 1/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	6.1% 6/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	3.0% 3/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Nervous system disorders Balance disorder	0.00% 0/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	8.1% 8/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Nervous system disorders Ataxia	0.00% 0/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	5.1% 5/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Nervous system disorders Dysarthria	0.00% 0/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	5.1% 5/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Blood and lymphatic system disorders Febrile neutropenia	0.00% 0/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	15.0% 3/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	1.0% 1/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.99% 1/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Blood and lymphatic system disorders Leukopenia	11.1% 1/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	15.0% 3/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	6.1% 6/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	5.0% 5/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Musculoskeletal and connective tissue disorders Musculoskeletal chest pain	0.00% 0/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	15.0% 3/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Infections and infestations Lip infection	0.00% 0/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	15.0% 3/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Infections and infestations Oral herpes	0.00% 0/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	15.0% 3/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	2.0% 2/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.99% 1/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Infections and infestations Infection	0.00% 0/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	10.0% 2/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.99% 1/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Infections and infestations Infusion site infection	0.00% 0/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	10.0% 2/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Infections and infestations Mucosal infection	0.00% 0/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	10.0% 2/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Infections and infestations Oral candidiasis	0.00% 0/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	10.0% 2/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	2.0% 2/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	2.0% 2/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Infections and infestations Upper respiratory tract infection	0.00% 0/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	10.0% 2/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	5.1% 5/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	3.0% 3/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Respiratory, thoracic and mediastinal disorders Pulmonary embolism	0.00% 0/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	15.0% 3/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	2.0% 2/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	4.0% 4/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Infections and infestations Nasopharyngitis	0.00% 0/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	6.1% 6/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	4.0% 4/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Metabolism and nutrition disorders Hypoalbuminaemia	0.00% 0/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	10.0% 2/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	2.0% 2/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	3.0% 3/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Metabolism and nutrition disorders Hypokalaemia	0.00% 0/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	10.0% 2/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	5.1% 5/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	6.9% 7/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Skin and subcutaneous tissue disorders Erythema	0.00% 0/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	15.0% 3/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	1.0% 1/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Skin and subcutaneous tissue disorders Rash maculo-papular	0.00% 0/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	15.0% 3/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	2.0% 2/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.99% 1/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Skin and subcutaneous tissue disorders Pruritus	0.00% 0/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	10.0% 2/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	3.0% 3/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Skin and subcutaneous tissue disorders Dry skin	0.00% 0/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	5.0% 1/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	3.0% 3/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	6.9% 7/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Respiratory, thoracic and mediastinal disorders Rhinorrhoea	0.00% 0/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	15.0% 3/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Respiratory, thoracic and mediastinal disorders Epistaxis	0.00% 0/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	5.1% 5/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	3.0% 3/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Psychiatric disorders Insomnia	0.00% 0/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	15.0% 3/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	2.0% 2/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	9.9% 10/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Psychiatric disorders Anxiety	0.00% 0/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	10.0% 2/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	4.0% 4/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.99% 1/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Psychiatric disorders Depressed mood	0.00% 0/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	10.0% 2/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	3.0% 3/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	3.0% 3/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Investigations Weight decreased	0.00% 0/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	15.0% 3/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	2.0% 2/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	3.0% 3/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Investigations White blood cell count decreased	0.00% 0/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	5.0% 1/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	7.1% 7/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	5.0% 5/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Injury, poisoning and procedural complications Procedural pain	0.00% 0/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	15.0% 3/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Injury, poisoning and procedural complications Infusion related reaction	0.00% 0/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	10.0% 2/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	2.0% 2/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	4.0% 4/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Vascular disorders Flushing	0.00% 0/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	10.0% 2/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	5.1% 5/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	2.0% 2/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Vascular disorders Palpitations	0.00% 0/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	15.0% 3/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	4.0% 4/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Eye disorders Photophobia	0.00% 0/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	10.0% 2/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Renal and urinary disorders Pollakiuria	0.00% 0/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	10.0% 2/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	2.0% 2/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	3.0% 3/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Reproductive system and breast disorders Vaginal haemorrhage	0.00% 0/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	10.0% 2/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	1.0% 1/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Musculoskeletal and connective tissue disorders Myalgia	0.00% 0/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	5.0% 1/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	9.1% 9/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	2.0% 2/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Musculoskeletal and connective tissue disorders Pain in extremity	0.00% 0/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	5.0% 1/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	7.1% 7/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.99% 1/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.
Ear and labyrinth disorders Vertigo	0.00% 0/9 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	0.00% 0/6 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	5.0% 1/20 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	8.1% 8/99 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.	2.0% 2/101 • TEAEs were defined as events occurring on or after Day 1 Cycle 1 up to and including 30 days after last dose, or Cycle 6, up to 7 months. Ph1b: All dose groups in Ph1b are combined and reported together due to small numbers in escalation phase: n=9 at 35mg/kg n=6 at 50mg/kg n=20 at 67.5mg/kg Ph2: Safety evaluable population is defined as all randomized patients who received any amount of study medication \[APR-246, carboplatin, or PLD\], regardless of duration of treatment.

Additional Information

Senior Medical Advisor

Aprea Therapeutics

Phone: 215-948-4119

Email: info@aprea.com

Results disclosure agreements

• Principal investigator is a sponsor employee
• Publication restrictions are in place